○Hidetoshi Sumimoto1, Koji Terada2, Agata Yasutoshi2, Yataro Daigo1,3 (1.Department of Medical Oncology, Shiga University of Medical Science, 2.Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, 3.Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo)
Session information
Mini-Oral Session
[MO16] Mini-Oral Session 16 Translational Research / Clinical Pharmacology 2(Immunotherapy)
【E】
Thu. Feb 17, 2022 2:10 PM - 3:10 PM Room 10 (Royal Room, 1F, The Prince Kyoto Takaragaike)
Chair:Kazuo Kasahara(Department of Respiratory Medicine, Kanazawa University),Shigehisa Kitano(The Cancer Institute Hospital of JFCR)
○Jun Oyanagi1,2, Yasuhiro Koh1,2, Yasuyuki Akiyama3, Atsushi Morimoto3, Koichi Sato1, Shunsuke Teraoka1, Daichi Fujimoto1, Nahomi Tokudome1, Atsushi Hayata1, Yuichi Ozawa1, Hiroaki Akamatsu1, Masanori Nakanishi1, Hiroki Ueda1, Nobuyuki Yamamoto1,2 (1.Internal Medicine III, Wakayama Medical University, 2.Center for Biomedical Sciences, CIMS, Wakayama Medical University, 3.Tosoh Corporation)
○Yuichi Ozawa1, Yuhei Harutani1, Jun Oyanagi1,2, Akamatsu Hiroaki1, Murakami Eriko1, Sato Kouichi1, Ryota Shibaki1, Takeya Sugimoto1, Atsushi Hayata1, Shunsuke Teraoka1, Tokudome Nahomi1, Hiroki Ueda1,3, Masanori Nakanishi1, Yasuhiro Koh1,2, Nobuyuki Yamamoto1,2 (1.Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University, 2.Center for Biomedical Sciences, Wakayama Medical University, 3.Oncology Center, Wakayama Medical University)
○Kazuko Sakai1, Marco Develasco1, Tomoyuki Nagai2, Kazuomi Ueshima2, Takaaki Chikugo3, Yurie Kura1, Takayuki Takahama4, Hidetoshi Hayashi4, Kazuhiko Nakagawa4, Masatoshi Kudo2, Kazuto Nishio1 (1.Department of Genome Biology, Kindai University Faculty of Medicine, 2.Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 3.Department of Diagnostic Pathology, Kindai University Faculty of Medicine, 4.Department of Medical Oncology, Kindai University Faculty of Medicine)
○Mohammed Hussein Safi1, Aman Wang1, Abdullah Shopit2, Dario Trapani3, Xiu Shan1, Jiwei Liu1 (1.Department of Oncology, First Affiliated Hospital of Dalian Medical University, 2.Medicine & Collage of Pharmacy, Department of Pharmacology, Dalian Medical University, Dalian, China, 3.IEO - Istituto Europeo di Oncologia)
○Yoshikawa Mai1, Nagira Yoji1, Nagira Morio1, Yoshida Tetsuya1, Yoshida Shinpei1, Soh Tetsuyoshi1, Wada Hisashi2,3, Ohkura Naganari4,5, Takahashi Tatsuya1 (1.SHIONOGI & CO., LTD., Japan, 2.Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 3.Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 4.Department of Frontier Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 5.Experimental Immunology, Immunology Frontier Research Center, Osaka University)
○Ryohei Nagai1, Morio Nagira1, Wataru Nogami1, Michinari Hirata1, Azumi Ueyama1, Mai Yoshikawa1, Naganari Ohkura2,3, Hisashi Wada4,5, Yoji Nagira1 (1.SHIONOGI & CO., LTD., 2.Department of Frontier Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 3.Experimental Immunology, Immunology Frontier Research Center, Osaka University, 4.Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, 5.Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University)